WIRED – 9 Jun 26
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.
美国食品药品监督管理局（FDA）近期批准了细胞再生疗法ER-100进行人体临床试验。虽然视力是其首要目标，但它也可能应用于多种与年龄相关的疾病。
Business Insider
The first-ever reverse-aging drug was just injected into a human
Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now being tested in humans.
周二，总部位于波士顿的生物技术初创公司 Life Biosciences 宣布，其首位患者已接受了细胞重编程注射，旨在逆转与年龄相关的疾病。
在这种情况下，注射物被注入了一名青光眼患者的一只眼球。该公司没有透露关于该患者的任何其他信息。 在接下来的六个月里，科学家们将观察这项技术的有效性，而医生们则会密切关注任何安全问题。
3 个帖子 - 2 位参与者
来源: LinuxDo 最新话题查看原文